Literature DB >> 10768093

Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity.

K C Baynes1, C A Beeton, G Panayotou, R Stein, M Soos, T Hansen, H Simpson, S O'Rahilly, P R Shepherd, J P Whitehead.   

Abstract

AIMS/HYPOTHESIS: Phosphoinositide 3-kinase (PI 3K) plays a central part in the mediation of insulin-stimulated glucose disposal. No genetic studies of this enzyme in human syndromes of severe insulin resistance have been previously reported.
METHODS: Phosphoinositide 3-kinase p85 alpha regulatory subunit cDNA was examined in 20 subjects with syndromes of severe insulin resistance by single strand conformational polymorphism and restriction fragment length polymorphism analyses. Insulin-stimulated phosphoinositide 3-kinase activity and recruitment into phosphotyrosine complexes of variants of p85 alpha were studied in transiently transfected HEK293 cells. Phosphopeptide binding characteristics of wild-type and mutant p85 alpha-GST fusion proteins were examined by surface plasmon resonance.
RESULTS: The common p85 alpha variant, Met326I1e, was identified in 9 of the 20 subjects. Functional studies of the Met326Ile variant showed it to have equivalent insulin-stimulated lipid kinase activity and phosphotyrosine recruitment as wild-type p85 alpha. A novel heterozygous mutation, Arg409Gln, was detected in one subject. Within the proband's family, carriers of the mutation had a higher median fasting plasma insulin (218 pmol/l) compared with wild-type relatives (72 mol/l) (n = 8 subjects, p = 0.06). The Arg409Gln p85 alpha subunit was associated with lower insulin-stimulated phosphoinositide 3-kinase activity compared with wild-type (mean reduction 15%, p < 0.05, n = 5). The recruitment of Arg409Gln p85 alpha into phosphotyrosine complexes was not significantly impaired. GST fusion proteins of wild-type and mutant p85 alpha showed identical binding to phosphopeptides in surface plasmon resonance studies. CONCLUSION/
INTERPRETATION: Mutations in p85 alpha are uncommon in subjects with syndromes of severe insulin resistance. The Met326Ile p85 alpha variant appears to have no functional effect on the insulin-stimulated phosphoinositide 3-kinase activity. The impaired phosphoinositide 3-kinase activity of the Arg409Gln mutant suggests that it could contribute to the insulin resistance seen in this family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768093     DOI: 10.1007/s001250050050

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  12 in total

1.  Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo.

Authors:  Lazaros C Foukas; Caroline A Beeton; Jorgen Jensen; Wayne A Phillips; Peter R Shepherd
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

2.  Single nucleotide polymorphisms within functional regions of genes implicated in insulin action and association with the insulin resistant phenotype.

Authors:  Malgorzata Malodobra; Agnieszka Pilecka; Bohdan Gworys; Rajmund Adamiec
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

3.  Mutations in PIK3R1 cause SHORT syndrome.

Authors:  David A Dyment; Amanda C Smith; Diana Alcantara; Jeremy A Schwartzentruber; Lina Basel-Vanagaite; Cynthia J Curry; I Karen Temple; William Reardon; Sahar Mansour; Mushfequr R Haq; Rodney Gilbert; Ordan J Lehmann; Megan R Vanstone; Chandree L Beaulieu; Jacek Majewski; Dennis E Bulman; Mark O'Driscoll; Kym M Boycott; A Micheil Innes
Journal:  Am J Hum Genet       Date:  2013-06-27       Impact factor: 11.025

4.  Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85alpha.

Authors:  Katrine Almind; Laurent Delahaye; Torben Hansen; Emmanuel Van Obberghen; Oluf Pedersen; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

5.  Phosphatidylinositol 3-kinase p85alpha regulatory subunit gene PIK3R1 haplotype is associated with body fat and serum leptin in a female twin population.

Authors:  Y Jamshidi; H Snieder; X Wang; M J Pavitt; T D Spector; N D Carter; S D O'Dell
Journal:  Diabetologia       Date:  2006-09-20       Impact factor: 10.122

6.  Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.

Authors:  Ryaz B Chagpar; Philip H Links; M Chris Pastor; Levi A Furber; Andrea D Hawrysh; M Dean Chamberlain; Deborah H Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

7.  Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation.

Authors:  M Dean Chamberlain; Tim Chan; Jennifer C Oberg; Andrea D Hawrysh; Kristy M James; Anurag Saxena; Jim Xiang; Deborah H Anderson
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

8.  Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.

Authors:  Ting-Yuan David Cheng; Jyoti Shankar; Gary Zirpoli; Michelle R Roberts; Chi-Chen Hong; Elisa V Bandera; Christine B Ambrosone; Song Yao
Journal:  Cancer Causes Control       Date:  2016-06-17       Impact factor: 2.506

9.  Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.

Authors:  Isabel Huang-Doran; Patsy Tomlinson; Felicity Payne; Alexandra Gast; Alison Sleigh; William Bottomley; Julie Harris; Allan Daly; Nuno Rocha; Simon Rudge; Jonathan Clark; Albert Kwok; Stefano Romeo; Emma McCann; Barbara Müksch; Mehul Dattani; Stefano Zucchini; Michael Wakelam; Lazaros C Foukas; David B Savage; Rinki Murphy; Stephen O'Rahilly; Inês Barroso; Robert K Semple
Journal:  JCI Insight       Date:  2016-10-20

10.  Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action.

Authors:  Inês Barroso; Jian'an Luan; Rita P S Middelberg; Anne-Helen Harding; Paul W Franks; Rupert W Jakes; D Clayton; Alan J Schafer; Stephen O'Rahilly; Nicholas J Wareham
Journal:  PLoS Biol       Date:  2003-10-13       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.